Mihaela Munteanu

1.7k citations

61 papers · 1.1k indexed · 1 hit paper · h-index 14

Impact in

Genetics top 5%
- Chronic Lymphocytic Leukemia Research
Pathology and Forensic Medicine top 2%
- Lymphoma Diagnosis and Treatment

Papers in ⓘ

Biological Psychiatry 4
Genetics 13
- Chronic Lymphocytic Leukemia Research 13

Co-authors: Ian W. Flinn (8 shared papers)John M. Burke (8 shared papers)Kathryn S. Kolibaba (6 shared papers)Samar Issa (6 shared papers)David MacDonald (7 shared papers)David Simpson (6 shared papers)Brad S. Kahl (7 shared papers)Tim E. Hawkins (6 shared papers)
Journals: Blood (6 papers)BMC Cancer (6 papers)Journal of Clinical Oncology (6 papers)Investigational New Drugs (4 papers)Cancer Chemotherapy and Pharmacology (2 papers)
Partner nations: United States Romania Australia

In The Last Decade

Mihaela Munteanu

54 papers receiving 1.1k citations

Hit Papers

align trajectories log scale

Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study 2014 · 419 citations

Peers

Countries citing papers authored by Mihaela Munteanu

Since Specialization

Citations

This map shows the geographic impact of Mihaela Munteanu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mihaela Munteanu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mihaela Munteanu more than expected).

Fields of papers citing papers by Mihaela Munteanu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mihaela Munteanu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mihaela Munteanu. The network helps show where Mihaela Munteanu may publish in the future.

Co-authors

The 25 scholars most cited alongside Mihaela Munteanu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mihaela Munteanu Line = papers co-authored together Mihaela Munteanu links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 61 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study Blood ·Ian W. Flinn, Richard van der Jagt, Brad S. Kahl, Peter Wood, Tim E. Hawkins, David MacDonald, Mark Hertzberg, Yiu‐Lam Kwan, David Simpson, Michael Craig, Kathryn S. Kolibaba, Samar Issa, Regina Clementi, Doreen M. Hallman, Mihaela Munteanu, Ling Chen, John M. Burke Hit paper breakdown →	2014	419
2	Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin) Leukemia ·Richard A. Larson, M. A. Boogaerts, Elihu H. Estey, Chatchada Karanes, EA Stadtmauer, Eric L. Sievers, Philippe Mineur, J M Bennett, M. S. Berger, CB Eten, Mihaela Munteanu, MR Loken, Jacques J. M. van Dongen, ID Bernstein, FR Appelbaum, (unknown)	2002	168
3	Increased arterial stiffness in children on haemodialysis Nephrology Dialysis Transplantation ·Adrian Covic, Nicoleta Mardare, Paul Gusbeth–Tatomir, O Brumaru, Cristina Gavrilovici, Mihaela Munteanu, Octavian Prisadă, David Goldsmith	2005	84
4	Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study Investigational New Drugs ·Anastasios Stathis, Ian W. Flinn, Sumit Madan, Kami J. Maddocks, Arnold S. Freedman, Steven Weitman, Emanuele Zucca, Mihaela Munteanu, M. Lia Palomba	2018	34
5	Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic‐ or accelerated‐phase chronic myeloid leukemia: Results with 24 months of follow‐up Cancer ·Jörge E. Cortes, Hagop M. Kantarjian, Delphine Réa, Meir Wetzler, Jeffrey H. Lipton, Luke P. Akard, H. Jean Khoury, Mauricette Michallet, Agnès Guerci‐Bresler, Charles Chuah, Andrzej Hellmann, Raghunadharao Digumarti, Purvish M. Parikh, Laurence Legros, Krzysztof Warzocha, Michele Baccarani, Elizabeth Li, Mihaela Munteanu, Franck E. Nicolini	2015	33
6	Quantitative morphological analysis of arrestin2 clustering upon G protein-coupled receptor stimulation by super-resolution microscopy Journal of Structural Biology ·Zinnia Truan, Laura Tarancón Díez, Claudia Bönsch, Sebastian Malkusch, Ulrike Endesfelder, Mihaela Munteanu, Oliver Hartley, Mike Heilemann, Alexandre Fürstenberg	2013	27
7	An Open-Label, Randomized Study of Bendamustine and Rituximab (BR) Compared with Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in First-Line Treatment of Patients with Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL): The Bright Study Blood ·Ian W. Flinn, Richard H. van der Jagt, Brad S. Kahl, Peter Wood, Tim E. Hawkins, David MacDonald, Mark Hertzberg, Yiu‐Lam Kwan, David Simpson, Michael Craig, Kathryn S. Kolibaba, Samar Issa, Mihaela Munteanu, Regina Clementi, Ling Chen, John M. Burke	2012	26
8	Results of a phase II study of bendamustine and ofatumumab in untreated indolent B cell non-Hodgkin’s lymphoma Annals of Hematology ·Myron S. Czuczman, Stephen P. Kahanic, Andres Forero, Glen M. Davis, Mihaela Munteanu, Éric Van Den Neste, Fritz Offner, Dominique Bron, Donald P. Quick, Nathan Fowler	2015	22
9	Phase II study of bendamustine combined with rituximab in relapsed/refractory mantle cell lymphoma: efficacy, tolerability, and safety findings Annals of Hematology ·Myron S. Czuczman, André Goy, Dominick Lamonica, Daniel A. Graf, Mihaela Munteanu, Richard H. van der Jagt	2015	22
10	Prognosis of colorectal cancer: clinical, pathological and therapeutic correlation. PubMed ·Liviu Vasile, Alexandru Olaru, Mihaela Munteanu, Iancu Emil Pleşea, Valeriu Şurlin, C Tudoraşcu	2012	22
11	Coordinate-based co-localization-mediated analysis of arrestin clustering upon stimulation of the C–C chemokine receptor 5 with RANTES/CCL5 analogues Histochemistry and Cell Biology ·Laura Tarancón Díez, Claudia Bönsch, Sebastian Malkusch, Zinnia Truan, Mihaela Munteanu, Mike Heilemann, Oliver Hartley, Ulrike Endesfelder, Alexandre Fürstenberg	2014	20
12	Potent Anti-HIV Chemokine Analogs Direct Post-Endocytic Sorting of CCR5 PLoS ONE ·Claudia Bönsch, Mihaela Munteanu, Irène Rossitto-Borlat, Alexandre Fürstenberg, Oliver Hartley	2015	16
13	Differences in Quality of Life Between Bendamustine-Rituximab and R-CHOP/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma Clinical Lymphoma Myeloma & Leukemia ·John M. Burke, Richard H. C. Van Der Jagt, Brad S. Kahl, Peter Wood, Tim E. Hawkins, David MacDonald, Mark Hertzberg, David Simpson, Michael Craig, Kathryn S. Kolibaba, Samar Issa, Mihaela Munteanu, Timothy W. Victor, Ian W. Flinn	2016	14
14	Preliminary report of the safety and efficacy of gemtuzumab ozogamicin (Mylotarg (R)) given in combination with cytarabine and daunorubicin in patients with acute myeloid leukemia ORCA Online Research @Cardiff (Cardiff University) ·Daniel J. DeAngelo, Donatella Russo, Sylvie Castaigné, Jordi Esteve, Alan K. Burnett, Anthony P. Goldstone, Martin S. Tallman, Ken Bradstock, Bob Löwenberg, L. Leopold, Mihaela Munteanu, Catharine B. Eten, Michael H. Berger	2001	14
15	¹⁸F-FDG PET for Measurement of Response and Prediction of Outcome to Relapsed or Refractory Mantle Cell Lymphoma Therapy with Bendamustine–Rituximab Journal of Nuclear Medicine ·Dominick Lamonica, Daniel A. Graf, Mihaela Munteanu, Myron S. Czuczman	2016	13
16	A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECHO-302) BMC Cancer ·Primo N. Lara, Luis J. Villanueva-Rivera, Carolina Ibáñez, Mustafa Erman, Jae‐Lyun Lee, Daniel Heinrich, Oleg Lipatov, Craig Gedye, Erhan Gökmen, Alejandro Acevedo, Andrey Semenov, Se Hoon Park, Rustem Gafanov, Fatih Köse, Mark M. Jones, Xiaoqi Du, Mihaela Munteanu, Rodolfo F. Perini, Toni K. Choueiri, Robert J. Motzer	2024	11
17	The safety and tolerability of epacadostat alone and in combination with pembrolizumab in patients with advanced solid tumors: results from a first-in-Japanese phase I study (KEYNOTE-434) Investigational New Drugs ·Toshihiko Doi, Yutaka Fujiwara, Kohei Shitara, Toshio Shimizu, Kan Yonemori, Nobuaki Matsubara, Izumi Ohno, Takahiro Kogawa, Yoichi Naito, Lance Leopold, Mihaela Munteanu, Naoyoshi Yatsuzuka, Shi Rong Han, Ayman Samkari, Noboru Yamamoto	2020	10
18	Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303/KEYNOTE-698 study BMC Cancer ·İrfan Çiçin, Elizabeth R. Plimack, Howard Gurney, Raya Leibowitz‐Amit, B. Yа. Alekseev, Francis Parnis, Avivit Peer, Andrea Necchi, Joaquim Bellmunt, Hiroyuki Nishiyama, Jason Clark, Mihaela Munteanu, Ritesh Kataria, Calvin Jia, Thomas Powles, Cora N. Sternberg	2024	10
19	Open-label Bendamustine Monotherapy for Pediatric Patients With Relapsed or Refractory Acute Leukemia Journal of Pediatric Hematology/Oncology ·Chris Fraser, Patrick A. Brown, Gail Megason, Hyo Seop Ahn, Bin Cho, Ivan I. Kirov, Lawrence S. Frankel, Richard Aplenc, Debra M. Bensen-Kennedy, Mihaela Munteanu, Jennifer Weaver, Paul Harker‐Murray	2013	10
20	Pembrolizumab (pembro) plus epacadostat or placebo for locally advanced or metastatic urothelial carcinoma (UC) after failure of first-line platinum-containing chemotherapy: KEYNOTE-698/ECHO-303. Journal of Clinical Oncology ·Thomas Powles, Joaquim Bellmunt, Daniel P. Petrylak, Lawrence Fong, Hiroyuki Nishiyama, Cora N. Sternberg, Chen Mei, Lei Pang, Mihaela Munteanu, Yufan Zhao, David C. Smith	2018	7

About Mihaela Munteanu

Mihaela Munteanu is a scholar working on Biological Psychiatry, Genetics, Hematology, General Energy and Nephrology, having authored 61 papers that have together received 1.1k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (14 papers), Chronic Lymphocytic Leukemia Research (13 papers), Cancer Immunotherapy and Biomarkers (12 papers), Acute Myeloid Leukemia Research (6 papers), Acute Lymphoblastic Leukemia research (6 papers), Chronic Myeloid Leukemia Treatments (6 papers), Cancer, Stress, Anesthesia, and Immune Response (5 papers) and Lung Cancer Treatments and Mutations (5 papers). The work is most often cited by research in Genetics (339 citations), Pathology and Forensic Medicine (548 citations), Oncology (538 citations), Hematology (177 citations) and Biological Psychiatry (30 citations). Mihaela Munteanu has collaborated with scholars based in United States, Romania and Australia. Frequent co-authors include Ian W. Flinn, John M. Burke, Kathryn S. Kolibaba, Samar Issa, David MacDonald, David Simpson, Brad S. Kahl, Tim E. Hawkins, Michael Craig and Peter Wood. Their work appears in journals such as Blood, BMC Cancer, Journal of Clinical Oncology, Investigational New Drugs and Cancer Chemotherapy and Pharmacology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact